Research network

This research network links people through identifiable publications. It is a curated map of documented connections, not a complete bibliometric analysis, a ranking or a claim that all collaborators support every subsequent Vision 2035 proposal.

Core author records

Valentyn Shapovalov — ORCID 0000-0002-9329-0195.
Valerii Shapovalov — ORCID 0000-0002-6696-6380.
Viktoriia Shapovalova — ORCID 0000-0003-4770-7292.
Oleksandr Veits — ORCID 0000-0003-3798-3816.
Andrii Diachenko — ORCID 0009-0001-1549-8820.
Alina Osyntseva — ORCID 0000-0003-1655-318X.
Anatolii Derkach — ORCID 0009-0009-5819-2467.
Olena Lavoshnyk — ORCID 0009-0000-0023-434X.

Iurii Titarenko — ORCID 0009-0002-8664-9013.

How connections are labelled

Coauthored means the named people appear together on the cited work. Institutional role means a dated institutional source names a role. Translation, editing and concept development are separate contributions and require their own evidence. A shared institution, surname or citation does not establish supervision, personal relationships or equal contribution.

Publication-linked chronology

Earlier pharmaceutical research

The 1989 paper on hydrazide derivatives of succinic heterylamides credits V. P. Chernykh, V. I. Kabachnyi, V. A. Shapovalova, L. A. Porokhnyak, O. V. Beletskaya and V. N. Savchenko. It anchors one strand of pharmaceutical chemistry, not a claim that Vision 2035 existed then. Primary DOI. See History and research foundations.

2021: access, forensic pharmacy and clinical topics

Andriy Gudzenko + Valentyn Shapovalov + Valeriy Shapovalov + Viktoriya Shapovalova: forensic-pharmacy analysis of complaints about medicine provision for privileged patient categories. DOI 10.31435/rsglobal_sr/30042021/7517; primary PDF. Gudzenko's identifier is ORCID 0000-0002-9040-007X.
Iryna Tukhar + Viktoriya Shapovalova + Valentyn Shapovalov + Valeriy Shapovalov: pancreatitis/comorbidity research, DOI 10.31435/rsglobal_sr/30072021/7591. Tukhar's identifier is ORCID 0000-0002-6827-402X.

The first PDF gives 20 March 2021 and the second 31 May 2021. Date-like strings embedded in their DOIs are not reliable substitutes for the publication dates supplied by the papers.

2024: professional education and forensic pharmacy

Valentyn Shapovalov + Oleksandr Veits: medical/pharmaceutical law, legal education and prevention of professional errors, primary record, DOI 10.53933/sspmlp.v4i4.169. Erasmus-related discussion should not be presented as proof of a completed funded programme.
Valentyn Shapovalov + Alina Osyntseva + Oleksandr Veits + Anatolii Derkach: alcohol-related harm and multidisciplinary forensic-pharmaceutical analysis, primary record, DOI 10.53933/sspmlp.v4i1.133.
Alina Osyntseva, sole author: medicine administration for tuberculosis pharmacotherapy under GSP requirements, primary record, DOI 10.53933/sspmpm.v4i2.140. This is an individual publication thread, not an invented coauthor connection.

2025: policy, rehabilitation and vaccine governance

Oleksandr Veits + Valentyn Shapovalov + Valerii Shapovalov + Andrii Diachenko: comparative US drug-trafficking policy and its possible relevance for Ukraine, 23 September 2025. Primary record, DOI 10.53933/e23ahw76.
Ivan Voloshyn-Haponov + Valerii Shapovalov + Andrii Diachenko + Natalia Matsko: an editorial on illicit psychoactive-substance trafficking, mental public health and rehabilitation, 14 July 2025. Primary record, DOI 10.53933/qn4b7s67. Identifiers: Voloshyn-Haponov, Matsko. Editorial proposals are not demonstrated treatment effects.
Valerii Shapovalov + Oleksandr Veits + Olena Lavoshnyk + Olga Gubaryeva: vaccine-circulation governance and pharmaceutical administration, 26 July 2025. Primary record. Gubaryeva: ORCID 0000-0002-5303-674X.

2025–2026: six-author conceptual books

Valentyn Shapovalov, Viktoriia Shapovalova, Valerii Shapovalov, Oleksandr Veits, Andrii Diachenko and Alina Osyntseva appear on the publisher records for:

The Concept of Medico-Pharmaceutical Law: Principles, Advantages and Risks of Integration (12 December 2025), DOI 10.53933/3qgntf55.
Vision 2035 – Medico-Pharmaceutical Law for Human Security (6 March 2026), DOI 10.53933/b91avw28.

Edition-level attribution: the 2025 publisher landing page places Viktoriia before Valerii; the PDF title page places Valerii before Viktoriia. Both name the same six people. Preserve the order of the edition being cited rather than interpreting this variation as a contribution ranking. The roster does not automatically apply to Revision 2027 or later articles.

2026: education, quality and administration

Viktoriia Shapovalova + Alina Osyntseva + Valentyn Shapovalov + Valerii Shapovalov: an OSPE pharmacognosy survey in Currents in Pharmacy Teaching and Learning 18(8):102668, DOI 10.1016/j.cptl.2026.102668, PMID 42048720. PubMed record. Fifty of 55 eligible students responded. The outcome concerns immediate perceptions, not objectively demonstrated improvement in professional competence.
Viktoriia Shapovalova + Alina Osyntseva + Valentyn Shapovalov: pharmaceutical cosmetology and cosmeceutical opportunities and limitations, DOI 10.37321/AMI.2026.1-30-38.
Oleksandr Veits + Valentyn Shapovalov + Valerii Shapovalov + Andrii Diachenko + Emma Nelson: comparative anti-corruption editorial, 16 July 2026, primary record, DOI 10.53933/fsr0fb46. This byline supports a publication connection, not broader biographical assertions about Nelson.
Valentyn Shapovalov + Andrii Diachenko + Anatolii Derkach: healthcare reform and legal relationships, primary record. The landing page gives 13 February 2026; an inconsistent PDF received date is not used here.

Additional quality and workforce connections

Viktoriia Shapovalova + Olena Lavoshnyk + Valentyn Shapovalov + Alina Osyntseva + Valerii Shapovalov: Ukraine–France Calendulae flos standards, comparative GAP/SWOT analysis, primary record, DOI 10.5281/zenodo.17923205.
Viktoriia Shapovalova + Olena Lavoshnyk + Alina Osyntseva + Anatolii Derkach + Valerii Shapovalov: pharmaceutical staffing, education, management and economics, primary record, DOI 10.52914/apmp.v6i2.77.

2024–2026: Iurii Titarenko and digital-health research

Iurii Titarenko (also published as Yurii; ORCID 0009-0002-8664-9013) adds a documented digital-health and pharmaceutical-research strand:

Yurii Titarenko + Valentyn Shapovalov: proposed technology approaches to falsified-medicine risks (2024), primary record, DOI 10.53933/sspmlp.v4i2.149.
Valentyn Shapovalov + Viktoriia Shapovalova + Alina Osyntseva + Valerii Shapovalov + Oleksandr Veits + Yurii Titarenko: formulation and quality-control research concerning paracetamol/ascorbic-acid tablets (2024), primary record, DOI 10.5281/zenodo.13820208. Not a clinical efficacy trial.
Oleksandr Nevzghoda + Alina Osyntseva + Valentyn Shapovalov + Iurii Titarenko + Viktoria Dovzhuk + Viktoriia Shapovalova + Valerii Shapovalov: combined antituberculosis medicines, market/registration/formulary analysis (2025), primary record, DOI 10.5281/zenodo.15662640.
Iurii Titarenko, sole author: narrative review of digital-health technology in personalized allergy therapy (16 March 2026), primary record, DOI 10.53933/wv26wm48. Further clinical research and regulation are called for in the abstract.

His separately catalogued bioresonance/bioquantum publications are attributed claims, not established clinical effects. They should not be merged with other digital-health or plasma-research topics into an endorsed treatment category.

Institutions are a different network

The SRUMPL management page, dated 16 May 2026, records roles associated with the scientific council, institutional leadership, pharmaceutical education, economics/tax, pharmacy and other sectors. These establish institutional associations only. Article affiliations may refer to other organizations or earlier appointments and should retain their date and source.

Profiles, uncertainty and maintenance

Verified public profile links are collected on the individual pages. A claimed ResearchGate profile is different from an automatically assembled publication/contributor record. No unverified profile is attached simply because a name matches; no citation/read counts are used as quality measures. Multiple records for the same DOI are treated as one work. Unresolved Scholar or ResearchGate matches remain omitted.